Salta al contenuto principale
Passa alla visualizzazione normale.

GIUSEPPE BADALAMENTI

Curriculum e ricerca

Insegnamenti

Anno accademico Codice della materia Nome della materia CFU Corso di studi
2024/2025 11652 ONCOLOGIA MEDICA (MODULO) 3 MEDICINA E CHIRURGIA
2024/2025 11652 ONCOLOGIA MEDICA (MODULO) 2 SCIENZE DELLE PROFESSIONI SANITARIE TECNICHE DIAGNOSTICHE
2024/2025 05403 ONCOLOGIA CLINICA C.I. 6 MEDICINA E CHIRURGIA
2024/2025 22310 PERCORSO INTERDISCIPLINARE PROFESSIONALIZZANTE IV C.I. 5 SCIENZE DELLE PROFESSIONI SANITARIE TECNICHE DIAGNOSTICHE

Pubblicazioni

Data Titolo Tipologia Scheda
2024 Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database Review essay (rassegna critica) Vai
2024 Evaluation of predictive factors for i-CLARAS (intraoperative complications in laparoscopic renal and adrenal surgery): a multicentre international retrospective cohort study Articolo in rivista Vai
2024 Roles of Tumor-Educated Platelets (TEPs) in the biology of Non-Small Cell Lung Cancer (NSCLC): A systematic review. “Re-discovering the neglected biosources of the liquid biopsy family” Articolo in rivista Vai
2024 Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer Articolo in rivista Vai
2024 Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors Review essay (rassegna critica) Vai
2024 Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients Articolo in rivista Vai
2024 The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors Articolo in rivista Vai
2024 Clinical recommendations for treatment of localized angiosarcoma: A consensus paper by the Italian Sarcoma Group Articolo in rivista Vai
2023 Gastrointestinal Stromal Tumors: Diagnosis, Follow-up and Role of Radiomics in a Single Center Experience Articolo in rivista Vai
2023 The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier? Articolo in rivista Vai
2023 Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab Articolo in rivista Vai
2023 Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay Articolo in rivista Vai
2023 Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence: A Report From the Italian Sarcoma Group Articolo in rivista Vai
2023 Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? Articolo in rivista Vai
2023 The Impact of O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation on the Outcomes of Patients with Leiomyosarcoma Treated with Dacarbazine Articolo in rivista Vai
2023 Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD) Articolo in rivista Vai
2023 Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis Review essay (rassegna critica) Vai
2023 KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study Articolo in rivista Vai
2023 A mutation-based radiomics signature predicts response to imatinib in Gastrointestinal Stromal Tumors (GIST) Articolo in rivista Vai
2023 CT and MR Imaging of Retroperitoneal Sarcomas: A Practical Guide for the Radiologist Review essay (rassegna critica) Vai
2022 Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel Articolo in rivista Vai
2022 Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement Articolo in rivista Vai
2022 Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses Articolo in rivista Vai
2022 Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial Articolo in rivista Vai
2022 Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a post-hoc analysis Articolo in rivista Vai
2022 Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors Articolo in rivista Vai
2022 Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study Articolo in rivista Vai
2022 Liquid biopsy and immunotherapy: is all that glitter gold? Capitolo o Saggio Vai
2022 Molecular tumor board Capitolo o Saggio Vai
2022 Future perspectives Capitolo o Saggio Vai
2022 Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case-series analysis from the Italian Rare Cancers Network Articolo in rivista Vai
2022 The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints Articolo in rivista Vai
2022 Deep Learning Networks for Automatic Retroperitoneal Sarcoma Segmentation in Computerized Tomography Articolo in rivista Vai
2022 Current clinically validated applications of liquid biopsy Capitolo o Saggio Vai
2021 Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pandemic Articolo in rivista Vai
2021 Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study Articolo in rivista Vai
2021 Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study Articolo in rivista Vai
2021 Prognostic role of plasma pd‐1, pd‐l1, pan‐btn3as and btn3a1 in patients affected by metastatic gastrointestinal stromal tumors: Can immune checkpoints act as a sentinel for short‐term survival? Articolo in rivista Vai
2021 Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic Articolo in rivista Vai
2021 Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study Articolo in rivista Vai
2021 Trabectedin for patients with advanced soft tissue sarcoma: A non-interventional, retrospective, multicenter study of the italian sarcoma group Articolo in rivista Vai
2021 Clinical prognostic factors in advanced epithelioid haemangioendothelioma: a retrospective case series analysis within the Italian Rare Cancers Network Articolo in rivista Vai
2021 Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors Review essay (rassegna critica) Vai
2021 Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study Articolo in rivista Vai
2021 Type and gene location of kit mutations predict progression-free survival to first-line imatinib in gastrointestinal stromal tumors: A look into the exon Articolo in rivista Vai
2021 Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs) Articolo in rivista Vai
2021 Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge Articolo in rivista Vai
2021 Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome Articolo in rivista Vai
2021 Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors Articolo in rivista Vai
2020 Fatal heart failure induced by pazopanib in a sarcoma patient previously treated with gemcitabine Articolo in rivista Vai
2020 Hereditary breast and ovarian cancer in families from southern Italy (Sicily)—Prevalence and geographic distribution of pathogenic variants in BRCA1/2 genes Articolo in rivista Vai
2020 Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 Articolo in rivista Vai
2020 Duodenal perforation as presentation of gastric neuroendocrine tumour: A case report Articolo in rivista Vai
2020 Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience Articolo in rivista Vai
2020 Recent advances in desmoid tumor therapy Articolo in rivista Vai
2020 Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet) Articolo in rivista Vai
2020 Mitotane concentrations influence outcome in patients with advanced adrenocortical carcinoma Articolo in rivista Vai
2020 Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor Articolo in rivista Vai
2020 Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: Results from an international, multi-institutional, retrospective analysis Articolo in rivista Vai
2020 Perioperative chemotherapy in poorly differentiated neuroendocrine neoplasia of the bladder: A multicenter analysis Articolo in rivista Vai
2020 Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions Articolo in rivista Vai
2020 Delaying surgery for patients with a previous SARS-CoV-2 infection Lettera Vai
2020 BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients Articolo in rivista Vai
2020 A “lymphocyte microrna signature” as predictive biomarker of immunotherapy response and plasma pd-1/pd-l1 expression levels in patients with metastatic renal cell carcinoma: Pointing towards epigenetic reprogramming Articolo in rivista Vai
2020 Surgical treatment of primary gastrointestinal stromal tumors (GISTs): Management and prognostic role of R1 resections Articolo in rivista Vai
2019 Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis Articolo in rivista Vai
2019 CT and MR imaging of chemotherapy-induced hepatopathy Articolo in rivista Vai
2019 Activity and safety of temozolomide in advanced adrenocortical carcinoma patients Articolo in rivista Vai
2019 Dedifferentiated retroperitoneal large liposarcoma and laparoscopic treatment: Is it possible and safe? The first literature case report Articolo in rivista Vai
2019 One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients Articolo in rivista Vai
2019 Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in metastatic melanoma patients? Abstract in atti di convegno pubblicato in rivista Vai
2019 Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group Articolo in rivista Vai
2019 Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials Articolo in rivista Vai
2019 How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis Articolo in rivista Vai
2019 Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? Review essay (rassegna critica) Vai
2019 Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives Articolo in rivista Vai
2019 Correction to: One shot NEPA plus dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) in sarcoma patients receiving multiple-day chemotherapy (Supportive Care in Cancer, (2019), 27, 9, (3593-3597), 10.1007/s00520-019-4645-3) Nota o commento Vai
2019 Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1 Articolo in rivista Vai
2019 How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials Articolo in rivista Vai
2019 Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Review essay (rassegna critica) Vai
2019 Molecular characterization of a long-term survivor double metastatic non-small cell lung cancer and pancreatic ductal adenocarcinoma treated with gefitinib in combination with gemcitabine plus nab-paclitaxel and mFOLFOX6 as first and second line therapy Articolo in rivista Vai
2019 Use of Cardioprotective Dexrazoxane Is Associated with Increased Myelotoxicity in Anthracycline-Treated Soft-Tissue Sarcoma Patients Articolo in rivista Vai
2019 Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters Articolo in rivista Vai
2019 Soft tissue sarcoma in Italy: From epidemiological data to clinical networking to improve patient care and outcomes Articolo in rivista Vai
2019 Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma? Articolo in rivista Vai
2018 A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors Articolo in rivista Vai
2018 Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study Articolo in rivista Vai
2018 Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib Articolo in rivista Vai
2018 The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis Articolo in rivista Vai
2018 Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial Articolo in rivista Vai
2018 Erratum to: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis (Scientific Reports, (2018), 8, 1, (13379), 10.1038/s41598-018-30780-4) Nota o commento Vai
2018 Body mass index as a risk factor for toxicities in patients with advanced soft-tissue sarcoma treated with trabectedin Articolo in rivista Vai
2017 Liquid Biopsy in Gastrointestinal Stromal Tumor Capitolo o Saggio Vai
2017 Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives Articolo in rivista Vai
2017 Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice Articolo in rivista Vai
2017 Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas Articolo in rivista Vai
2016 Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma Articolo in rivista Vai
2016 Erratum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases (Scientific Reports (2015) 5 (18670) DOI: 10.1038/srep18670) Nota o commento Vai
2016 Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond Articolo in rivista Vai
2016 Clinical Impact of Cystatin C/Cathepsin L and Follistatin/Activin A Systems in Breast Cancer Progression: A Preliminary Report Articolo in rivista Vai
2015 Targeted Therapies in Gastrointestinal Stromal Tumors Capitolo o Saggio Vai
2015 Lack of Correlation between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: A Retrospective Study Articolo in rivista Vai
2015 Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? Articolo in rivista Vai
2015 Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis Articolo in rivista Vai
2015 Into the wild of long non-coding RNA in gastrointestinal stromal tumors (GISTs) to explore new prognostic/predictive biomarkers Proceedings Vai
2015 Natural History of Non-Small-Cell Lung Cancer with Bone Metastases Articolo in rivista Vai
2014 Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour Articolo in rivista Vai
2013 Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma Articolo in rivista Vai
2013 Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Articolo in rivista Vai
2013 Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options Articolo in rivista Vai
2013 Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. Articolo in rivista Vai
2012 Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study Articolo in rivista Vai
2012 PML expression in soft tissue sarcoma: Prognostic and predictive value in alkylating agents/antracycline-based first line therapy. Articolo in rivista Vai
2011 EFFICACY OF ZOLEDRONIC ACID IN PATIENTS WITH RENAL CANCER METASTATIC TO BONE Proceedings Vai
2010 The use of pegylated liposomal doxorubicin (PLD) in association with weekly paclitaxel as second line therapy in metastatic bladder carcinoma: final results Proceedings Vai
2010 PML down-regulation in soft tissue sarcomas. Articolo in rivista Vai
2010 Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Articolo in rivista Vai
2010 Serum follistatin in patients with prostate cancer metastatic to the bone Articolo in rivista Vai
2010 PML down-regulation in soft tissue sarcomas Articolo in rivista Vai
2010 EFFICACY OF ZOLEDRONIC ACID IN PATIENTS WITH COLORECTAL CANCER METASTATIC TO BONE Proceedings Vai
2010 PML expression in soft tissue sarcoma: prognostic value in alkilating agents/anthracyclin based first line therapy Proceedings Vai
2009 Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C. Articolo in rivista Vai
2009 Antiemetic prophylaxis containing Palonosetron (P) alone or in combination with Aprepitant (A) in the treatment of advanced soft tissue sarcoma (STS) patients with epirubicin and ifosfamide Abstract in rivista Vai
2009 Comparison between palonosetron(P) and aprepitant (A) versus palonosetron alone for antiemetic prophylaxis in advanced soft tissue sarcoma (STS)patients treated with epirubicin and ifosfamide. Abstract in rivista Vai
2009 GIST, Tumori stromali gastrointestinali (Gist: linee guida diagnostico-terapeutiche) Monografia Vai
2008 Gemcitabine plus metronoic capecitabine as second/third line chemotherapy in advanced adrenocortical carcinoma. A multicenter phase II trial. Abstract in rivista Vai
2008 Gists eredo familiari e pediatrici: aspetti biomolecolari e clinici. Capitolo o Saggio Vai
2008 The Use of Lenograstim in the prevention of chemotherapy induced neutropenia in patiets with soft tissue sarcoma (STS) Proceedings Vai
2008 Pegylated liposomal doxorubicin (PLD) and weekly paclitaxel (P) as second line chemotherapy in metastatic bladder cancer. Abstract in rivista Vai
2008 Antifungal prophylaxis of oropharyngeal mucositis with itraconazole during adjuvant chemotherapy in colorectal cancer (CRC)patients. Abstract in rivista Vai
2007 MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. Articolo in rivista Vai
2007 Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis. Articolo in rivista Vai
2007 Founder mutations in BRCA1 and BRCA2 genes Articolo in rivista Vai
2007 Effects of Zoledronic Acid on Cathepsin K circulating levels in patients with bone metastasis. Proceedings Vai
2007 4843delC of the BRCA1 gene is a possible founder mutation in Southern Italy (Sicily). Articolo in rivista Vai
2007 Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features Articolo in rivista Vai
2007 The role of Aurora-A inhibitors in cancer therapy. Articolo in rivista Vai
2006 Persistance of residual vein thrombosis after an episode of deep vein thrombosis of the lower limbs and the risk of new cancer and cardiovascular disease. Proceedings Vai
2006 GIST Proceedings Vai
2006 A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer. Articolo in rivista Vai
2006 A case of guillain-barre syndrome in a patient with non small cell lung cancer treated with chemotherapy Articolo in rivista Vai
2006 Ductal lavage: a way of carefully tracing the breast-secreting duct Articolo in rivista Vai
2006 A case of squamocellular uterine cervix carcinoma metastatic to the skin with enterocutaneous fistula. Articolo in rivista Vai
2006 A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma Articolo in rivista Vai
2006 Clinical significance of Activin A serum levels in patients with primary osteoporosis: a preliminary report Proceedings Vai
2006 Activin A circulating levels in patients with osteoporosis or bone metastasis from breast cancer Proceedings Vai
2006 Activin A and matrix metalloproteinase -2 and -9 blood levels as gauges of bone metastatic spread Proceedings Vai
2006 Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers Articolo in rivista Vai
2006 Activin a and matrix metalloproteinase-2 and -9 blood levels as gauges of bone metastatic spread. In: Tumor microenvironment:Heterotypic interactions. Proceedings Vai
2006 Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases. Articolo in rivista Vai
2006 P16 ink4A, p53 alterations and S phase fraction are predictive of clinical outcome in laryngeal squamous cell carcinoma. Proceedings Vai
2006 Low dose oral chemotherapy for hormone refractory prostate carcinoma estramustine phosphate versus estramustine phosphate and etoposide. A Randomized phase II study of GSTU foundation Proceedings Vai
2006 Ductal lavage: a valid method of risk assessment and of early diagnosis in breast cancer. Proceedings Vai
2006 Activin A circulating levels in patients with bone metastasis from breast or prostate cancer Articolo in rivista Vai
2006 Ductal Lavage: a valid method of risk assessment and of early diagnosis in breast cance Proceedings Vai
2006 New potential circulating markers for the therapeutic monitoring of metastatic bone disease. Proceedings Vai
2005 ACTIVIN A CIRCULATING LEVELS IN PATIENTS WITH PRIMARY OSTEOPOROSIS OR BONE METASTASES FROM BREAST CANCER Articolo in rivista Vai
2005 The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers Articolo in rivista Vai
2005 Activin A circulating levels in Patients with primary osteoporosis or bone metastases from brest cancer Proceedings Vai
2005 The use of somatostatin analogues in metastatic hormone refractory and chemo resistant prostate cancer with neuroendocrine differentiation. Proceedings Vai
2005 Surgical Treatment of Extravasation Injuries Articolo in rivista Vai
2004 Cardiotossicità e Cardioprotezione. Altro Vai
2004 Detection and clinical relevance of free-circulating tumor DNA in blood of patients with colorectal cancer. Proceeding of ICACT Fifteenth International Congress on Anticancer Treatment February 9th 12th 2004, Paris accepted for oral presentation Proceedings Vai
2004 A phase II study of Oxaliplatin Capecitabine chemotherapy in metastatic breast cancer patients pretreated with anthracyclines and taxanes Proceedings Vai
2004 Weekly paclitaxel and Pegylated liposomal doxorubicin as first line treatment in metastatic breast cancer patients Proceedings Vai
2004 Weekly Paclitaxel (T) and pegylated liposomal Doxorubicin (PLD) as first line treatment in metastatic breast cancer (MBC) patients.VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 Proceedings Vai
2004 Zoledronic acid-induced variations in MMP-2, MMP-9 and uPA plasma concentrations in patients with metastatic bone disease Proceedings Vai
2004 Detection and clinical relevance of free-circulating tumor DNA in blood of patients with colorectal cancer Proceedings Vai
2004 A phase 2 study of Oxaliplatin ( O ) – Capecitabine( C ) chemotherapy in metastatic breast cancer ( MBC ) patients pretreated with Anthracyclines and taxanes VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 Proceedings Vai
2004 A phase II study of capecitabine oxaliplatin chemotherapy in metastatic breast cancer patients pretreated with anthracyclines and taxanes Proceedings Vai
2004 Pegylated Liposomal Doxorubicin and weekly paclitaxel as first line treatment in metastatic breast cancer Proceedings Vai